Sulfamoyl substituted phenethylamine intermediates
US5391825A · kind A · utility
6Cited by
7References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 28, 1993 |
| Grant date | Feb 21, 1995 |
| Priority date | — |
| Expiry date | Dec 28, 2013 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C309/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Pharmaceutical compositions are provided for the treatment of disorders in a subject, such as hypertension, congestive heart failure, angina pectoris, lower urinary tract dysfunction and prostatic hypertrophy. The compositions when administered to a subject produce an .alpha.-adrenergic blocking action and contain as an active ingredient sulfamoyl-substituted phenethylamine derivatives, such as optically active 5-2-[2-(2-ethoxyphenoxy)ethylamino]-2-methylethyl-2-methoxybenzenesulfonam ide, and a pharmaceutically acceptable carrier.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.